Repository logo

A world allergy organization international survey on diagnostic procedures and therapies in drug allergy/hypersensitivity.

Change log


Thong, Bernard Yu-Hor 
Mirakian, Rita 
Castells, Mariana 
Pichler, Werner 
Romano, Antonino 


OBJECTIVE: To study the diagnostic and treatment modalities used in drug allergy/hypersensitivity among members of the World Allergy Organization (WAO). METHODS: A questionnaire comprising 39 questions was circulated electronically to member societies, associate member societies, and regional and affiliate organizations of WAO between June 29, 2009, and August 9, 2009. RESULTS: Eighty-two responses were received. Skin testing was used by 74.7%, with only 71.4% having access to penicillin skin test reagents. In vitro-specific IgE tests were used by 67.4%, and basophil activation test was used by 54.4%. Lymphocyte transformation tests were used by 36.8% and patch tests by 54.7%. Drug provocation tests were used by 68.4%, the most common indication being to exclude hypersensitivity where history/symptoms were not suggestive of drug hypersensitivity/allergy (76.9%). Rapid desensitization for chemotherapy, antibiotics, or biologic agents was used by 69.6%. Systemic corticosteroid was used in the treatment of Stevens-Johnson syndrome by 72.3%, and high-dose intravenous immunoglobulins in toxic epidermal necrolysis by 50.8%. Human leukocyte antigen screening before prescription of abacavir was used by 92.9% and before prescription of carbamazepine by 21.4%. CONCLUSIONS: Results of this survey form a useful framework for developing educational and training needs and for improving access to drug allergy diagnostic and treatment modalities across WAO member societies.


RIGHTS : This article is licensed under the BioMed Central licence at which is similar to the 'Creative Commons Attribution Licence'. In brief you may : copy, distribute, and display the work; make derivative works; or make commercial use of the work - under the following conditions: the original author must be given credit; for any reuse or distribution, it must be made clear to others what the license terms of this work are.


32 Biomedical and Clinical Sciences, 3202 Clinical Sciences, Clinical Research, Food Allergies, Health Services, 5.1 Pharmaceuticals, 5 Development of treatments and therapeutic interventions, 6 Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Inflammatory and immune system

Journal Title

World Allergy Organ J

Conference Name

Journal ISSN


Volume Title


Elsevier BV